Jade Biosciences (NASDAQ:JBIO) Shares Gap Up – What’s Next?

Jade Biosciences, Inc. (NASDAQ:JBIO)’s share price gapped up prior to trading on Monday . The stock had previously closed at $16.82, but opened at $17.90. Jade Biosciences shares last traded at $18.2050, with a volume of 432,648 shares changing hands.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Lifesci Capital raised shares of Jade Biosciences to a “strong-buy” rating in a research note on Friday, March 6th. Zacks Research upgraded shares of Jade Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. Wall Street Zen cut shares of Jade Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings downgraded shares of Jade Biosciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 16th. Finally, Guggenheim reissued a “buy” rating and set a $47.00 price objective on shares of Jade Biosciences in a report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $47.12.

Jade Biosciences Stock Up 16.3%

The firm has a 50-day moving average of $21.02 and a two-hundred day moving average of $16.94. The company has a market capitalization of $965.73 million, a PE ratio of -9.65 and a beta of 1.45.

Jade Biosciences (NASDAQ:JBIO) last announced its earnings results on Thursday, May 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.05). Equities analysts predict that Jade Biosciences, Inc. will post -2.54 EPS for the current fiscal year.

Institutional Trading of Jade Biosciences

A number of large investors have recently modified their holdings of the stock. Janus Henderson Group PLC acquired a new position in shares of Jade Biosciences during the 1st quarter worth approximately $43,557,000. RA Capital Management L.P. grew its holdings in Jade Biosciences by 245.6% during the 4th quarter. RA Capital Management L.P. now owns 3,671,083 shares of the company’s stock valued at $56,645,000 after buying an additional 2,608,757 shares during the last quarter. Baker BROS. Advisors LP acquired a new stake in Jade Biosciences during the 4th quarter valued at $25,323,000. Remedium Capital Partners LLC purchased a new position in Jade Biosciences during the fourth quarter worth $24,345,000. Finally, Aberdeen Group plc purchased a new position in Jade Biosciences during the fourth quarter worth $13,382,000.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.